4SC develops small molecule drugs for the treatment of cancer in indications with a high unmet medical need. In doing so, we strive to offer patients treatment options that are more effective and better tolerated as well as a better quality of life.
The 4SC product pipeline currently comprises two drug candidates in clinical development, resminostat and domatinostat (4SC-202), and a third compound, 4SC-208, that is in pre-clinical development.
CEO Jason Loveridge, Ph.D., on fast-to-market strategy for development of 4SC’s core assets resminostat, domatinostat (4SC-202) and 4SC-208
as of August 2017
Resminostat is an orally administered histone deacetylase (HDAC) inhibitor with an innovative mechanism of action that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other anti-cancer drugs.
Domatinostat is an orally administered histone deacetylase (HDAC) inhibitor with a unique mode of action that was designed to strengthen the body’s own anti-tumor immune response. Domatinostat “opens” the tumor microenvironment and encourages infiltration of immune cells into the tumor.
4SC-208 is a small molecule specifically targeting two kinases crucial for Hedgehog/GLI signaling. Inhibition of the Hedgehog/GLI pathway has emerged as a highly effective strategy in obstructing the tumorigenic capacity of cancer stem cells, which are responsible for metastasis and the recurrence of tumors.
Assets available for out-licensing
4SC is focused on developing small molecule drugs for the treatment of cancer. All other assets are available for partnering or out-licensing.
4SC has out-licensed drug candidates to several national and international pharma and biotech companies.